Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
Reduced CDX2 was associated with lymph node metastasis (p = 0.0167), distant metastasis (p = 0.0123), and unfavorable survival (multivariate analysis: p = 0.0008; HR (95%CI) 0.922 (0.988-0.997)) as well as BRAF<sup>V600E</sup>, mismatch repair deficiency, and CpG island methylator phenotype.
|
30257705 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
Patients with CDX2-negative metastatic CRC were significantly more likely to be female, and to have right-sided primary tumors, poorly differentiated histologic features, and distant lymph node metastasis.
|
27726953 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.090 |
PosttranslationalModification
|
disease |
BEFREE |
The methylation of the CDX2 promoter was associated with enhanced lymph node metastases and shorter survival time (p = 0.0273), but was independent of tumor stage, tumor differentiation, gender, and age.
|
27754705 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
CDX2 might be valuable in terms of narrowing the possible sites of origin to be considered in the setting of SCC with unknown primary presenting with inguinal lymph node metastasis.
|
23105122 |
2013 |
Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
The CDX2/CK20 phenotype was associated with older age (above 56 y), higher stage (stage III or IV), deep invasion (pT3 or pT4), lymph node metastasis (pN1 or pN2), poor differentiation (nonmedullary/non-signet ring cell type), the mutation of BRAF, and CIMP-H status among MSI-H CRCs.
|
24025523 |
2013 |
Secondary malignant neoplasm of lymph node
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
ITLN-1 positivity in gastric cancer was positively correlated with tumor differentiation (P = 0.001) and CDX2 expression (P < 0.001), and inversely correlated with depth of invasion (P = 0.007), lymph node metastasis (P = 0.001), distant metastasis (P = 0.014), clinical stage (P = 0.006), Ki-67 expression (P = 0.001), and heparanase expression (P < 0.001), without correlation with age, gender, tumor location, or tumor size.
|
22083213 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
Cdx2-positive cases were significantly associated with higher male-to-female ratio (RR=1.27, 95% CI: 1.17-1.38, P<0.00001 fixed-effect), lower (I+II) clinical stage (RR=1.63, 95% CI: 1.42-1.87, P<0.00001 fixed-effect), better histologic differentiation (RR=1.54, 95% CI: 1.34-1.76, P<0.00001 fixed-effect), and lower rate of vascular invasion (RR=1.23, 95% CI: 1.08-1.41, P=0.002 fixed-effect) and lymph node metastasis (RR=1.52, 95% CI: 1.33-1.73, P<0.00001 fixed-effect), as well as higher 5-year survival rate (HR=2.22, 95% CI: 1.78-2.75, P<0.00001 fixed-effect).
|
23181722 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.090 |
Biomarker
|
disease |
BEFREE |
Of the 62 cases of CRC examined, 43 (69.4%) and 39 (62.9%) were positive for CDX2 and HIF-1alpha, respectively, such that their expression was correlated with differentiation grade, tumor stage and lymph node metastasis (chi2 test, p<0.01).
|
20514449 |
2010 |
Secondary malignant neoplasm of lymph node
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Recently, an inverse correlation between CDX2 expression and tumor grade, tumor stage and lymph node metastasis in colorectal adenocarcinomas has been reported.
|
19795349 |
2009 |